Timing Effect of Ultrasound-Guided PVB After Robotic Cardiac Surgery

Randomized, Single-Blinded Study to Evaluate the Timing Effect of Ultrasound-Guided Paravertebral Block in Patients Undergoing Robotic Mitral Valve Repair Procedure

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04298580

Enrollment

Registered

2020-03-06

Start date

2020-09-01

Completion date

2021-03-31

Last updated

2020-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Surgery, Nerve Block

Keywords

Postoperative pain

Brief summary

This study is to evaluate whether the administration of ultrasound-guided paravertebral block (PVB) after surgery would produce better postoperative pain control and fast postoperative recovery after Robotic cardiac surgery. Half of participants will receive PVB before surgery, while the other half will receive PVB at the end of surgery.

Detailed description

Ultrasound-guided PVB (either before surgery, or after surgery) is the standard postoperative pain management for Robotic cardiac surgery. This technique is to inject local anesthetic (numb medication) around nerve to decrease pain. But the optimal time of PVB is unknown. The administration of PVB before surgery can help pain control during the surgery and after surgery. But the duration of PVB could be reduced because surgery itself can last 5-6 hrs. The PVB after surgery will not provide pain control during surgery, but may provide longer pain control after surgery, and may help participants faster recovery after surgery.

Interventions

PROCEDUREPVB block

PVB block before surgery versus after surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Outcomes Assessor)

Masking description

Outcomes assessor will be blinded to study group

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Age ≥ 18 yrs 2. ASA I-IV 3. Either gender

Exclusion criteria

1. Refusal to participate in the study 2. Age\< 18 yrs 3. Contraindications to regional blockage including but not limited to: 1. Patient refusal to regional blockade 2. Infection at the site of needle insertion 3. Systemic infection 4. Bleeding diathesis or coagulopathy

Design outcomes

Primary

Measure	Time frame	Description
Durations of ICU and hospitalization	2-6 days	Duration (days) of ICU stay, and duration of hospital stay

Secondary

Measure	Time frame	Description
Pain intensity measure	2-3 days	self reported pain intensity at every 4 hour while in the ICU. It is a scored 0-10 (0 = no pain, 10 + pain as bad as can be)

Contacts

Primary ContactManxu Zhao, MD

manxu.zhao@cshs.org310-423-5841

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026